Eli Lilly to seek approval of Evista to treat breast cancer

By Elaine Rigoli

Tampa, Fla., April 17 - Eli Lilly and Co. said results from the Study of Tamoxifen and Raloxifene (STAR) trial, along with data from the Raloxifene Use for the Heart (RUTH) trial, will form the basis of a submission to the Food and Drug Administration supporting Evista (raloxifene HCl) for the reduction of invasive breast cancer risk in postmenopausal women.

The STAR results add to the growing body of scientific knowledge about the potential for therapies to reduce breast cancer risk, the company said in a news release.

Evista is marketed in the United States for the prevention and treatment of osteoporosis in postmenopausal women.

Raloxifene is not approved by the FDA for preventing or reducing the risk of cardiovascular disease or invasive breast cancer, the release said.

RUTH is a multi-national, double-blind, placebo-controlled study with primary endpoints of invasive breast cancer risk and cardiovascular risk reduction.

Eli Lilly, a pharmaceutical products company, has headquarters in Indianapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.